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Abstract
Background: Experimental data demonstrated that concurrent anti-angiogenic treatment with sunitinib may
improve the efficacy of radiation therapy (RT). Here we report the results of a phase I trial performed within the
German Interdisciplinary Sarcoma Group (GISG-03) of combined sunitinib and RT for neoadjuvant treatment of
locally advanced soft tissue sarcoma (STS).
Methods: The primary endpoint of the study was to explore the recommended dose of sunitinib combined with
RT for subsequent trials. Treatment response, postoperative complications after tumor resection and toxicity
according to CTCAE 4.0 were secondary endpoints. The study used a 3 + 3 design. Patients received either 25 mg
(dose level 1) or 37.5 mg (dose level 2) sunitinib two weeks prior to and throughout RT (28 × 1.8 Gy). Surgery was
scheduled 5–8 weeks after completion of neoadjuvant treatment. Study registration: NCT01498835.
Results: Six patients were enrolled in dose level 1 and three patients in dose level 2. Median tumor size was 11 cm.
Tumors were located in the retroperitoneum (4/9), lower leg (3/9) or trunk (2/9). At dose level 1, 1/6 patients
developed dose limiting lymphopenia. At dose level 2, no patient developed dose limiting toxicity. Most frequent
toxicities were hematological (8/9) and oral (5/9). Dose adjustments of sunitinib were necessary in 5/9 patients. All
patients received full dose RT and underwent tumor resection (8/9 R0 and 1/9 R1). Local toxicity of RT did not
exceed Grade 2. 2/9 patients had postoperative complications requiring re-intervention. Treatment response
according to RECIST was as follows: partial response 1/9, stable disease 7/9, and progressive disease 1/9.
Pathological examination revealed ≥ 95 % tumor necrosis in 3/9 resected specimens.
Conclusions: Combined sunitinib and RT was tolerable as neoadjuvant treatment for locally advanced STS patients
regardless of tumor localization. The recommended sunitinib dose for subsequent trials is 37.5 mg.
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Introduction
Soft tissue sarcomas (STS) are a rare group of mesenchy-
mal tumors comprising approximately 1 % of all malig-
nancies [1]. Surgical resection and pre- or postoperative
irradiation is the standard treatment for locally advanced
STS of the extremities [2, 3]. In retroperitoneal STS pre-
operative radiation therapy (RT) is currently under investi-
gation in a phase III trial after cohort studies had
demonstrated that preoperative RT may decrease local re-
currence and improve overall survival [4, 5]. (EORTC
STRASS trial ClinicalTrials.gov Identifier: NCT01344018)
Despite improvements in irradiation techniques such as
intensity modulated radiation therapy (IMRT) local recur-
rence rates of large, high grade STS is still up to 20 % in
extremity and 40 % in retroperitoneal tumors and there is
a definitive need to improve local therapy [6, 7].
Receptor tyrosine kinase inhibitors such as sunitinib
exhibit antiproliferative and anti-angiogenic properties
[8]. Experimental data demonstrated that concurrent
treatment with sunitinib and RT is more effective than
RT alone in engineered mouse models of soft tissue sar-
coma [9]. Thus, concurrent treatment seems to lead to
additive effects. Jain et al. postulated even synergistic ef-
fects if anti-angiogenic treatment is administered up-
front RT by “normalizing” the chaotic neovascularization
of tumors [10]. Vascular normalization may then lead to
decreased tumor hypoxia and consequently to increased
RT efficacy.
Here we report the results of a phase I trial of concur-
rent sunitinib and RT in patients with locally advanced
soft tissue sarcoma conducted within the German Inter-
disciplinary Sarcoma Group (GISG). The rationale and




This was an open-label, single-arm, single center phase I
trial performed within the GISG. The study intervention
was administration of sunitinib concurrently to pre-
operative irradiation in patients with soft tissue sarcoma.
The primary endpoint of the study was to determine the
recommended phase II dose of sunitinib given two
weeks before and throughout standard RT as preopera-
tive treatment. Secondary endpoints were toxicity, radio-
graphic and pathologic treatment response as well as
morbidity of tumor resection. A standard dose escalation
3 + 3 design with two dose levels was used.
The sponsor of the trial was the University of
Heidelberg, Germany. The study was funded by the
German Research Foundation (DFG, grant number JA
2030/1) and the Medical Faculty Mannheim, University
of Heidelberg, Germany. The study medication was pro-
vided by Pfizer Oncology Germany. Pfizer had no
influence on design, conduction or publication of the
trial. The study was approved by the Ethics Committee
II of the University of Heidelberg and the Federal
Agency for Drugs and Medical Devices, Germany
(BfArM). The trial was registered at clinicaltrials.gov
(NCT01498835). The trial was performed on an out-
patient basis. All patients were treated at the Mannheim
University Medical Center (UMM), University of
Heidelberg, Germany.
Patient selection
Patients with locally advanced primary soft tissue sar-
coma that required preoperative irradiation and tumor
resection were included into the trial. The protocol
allowed recruitment of patients with primary tumors but
also with local recurrences or metachronous solitary
metastatic lesions if the treatment decision was to per-
form RT and subsequent surgery. All tumors had to be
resectable and biopsy-proven STS. Patients needed to
have an age of 18 years or older with ECOG status 0 or
1 and normal organ function (left ventricular ejection
fraction, kidney, liver, and bone marrow). Main exclusion
criteria were metastatic disease (with the above men-
tioned exception), prior therapy with receptor tyrosine
kinase inhibitors or conventional chemotherapy or his-
tory of myocardial infarction, congestive heart failure,
stroke, thrombosis or embolism or uncontrolled medical
disease such as arterial hypertension or diabetes
mellitus.
Treatment regimen
The treatment plan was to administer sunitinib two
weeks prior to and during intensity modulated radiation
therapy (IMRT, 28 × 1.8 Gy) and to resect the tumors 5
to 8 weeks after the end of the neoadjuvant treatment.
Adjuvant chemotherapy was not administered. All pro-
cedures were described in detail before [11].
Sunitinib malate was orally administered as hard gel-
atin capsules of 25 or 12.5 mg. Sunitinib dose was esca-
lated according to a traditional 3 + 3 design. Dose level 1
was 25 mg and dose level 2 was 37.5 mg. No further
dose escalation was planned. Intrapatient dose escalation
was not permitted. Sunitinib was taken starting 2 weeks
prior to radiation therapy, continued throughout radi-
ation therapy and stopped on the final day of radiation
therapy. Sunitinib was administered continuously and
not with a 4 weeks on/2 weeks off regimen.
Intensity-modulated radiation therapy (IMRT) was ap-
plied according to standard protocols at the Mannheim
University Medical Center. The dose of IMRT was
50.4 Gy (median planning target volume (PTV) dose)
administered in 28 fractions within 5.5 weeks. Dose pre-
scription was performed at the median dose in the PTV
with the 90 % isodose line covering the PTV. A CT
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simulation was performed to define the gross tumour
volume (GTV). In case of retroperitoneal sarcomas, the
clinical target volume (CTV) was the GTV with a
1,5 cm margin axially. The margin placed around the
GTV in the superior-inferior direction was 2,5 cm. The
planning target volume was the CTV with a 5 mm mar-
gin. In case of extremity STS the CTV margins were
2,5 cm axially and 4,5 cm in the superior-inferior direc-
tion. The dose constraint for the small intestine was
45 Gy at the maximum and the mean dose for kidneys
were not greater than 10 Gy. Treatment was performed
using step-and-shoot IMRT. A strip of 2–3 cm skin was
spared in case of extremity STS.
Surgery was scheduled 5–8 weeks after completion of
neoadjuvant treatment. Surgery was planned as compart-
ment or wide resection in extremity STS. In retroperiton-
eal sarcoma, the surgical approach was a multivisceral
resection including adjacent organs (e.g. colectomy, neph-
rectomy, splenectomy, distal pancreatectomy) and resec-
tion of abdominal wall musculature or, respectively, the
psoasmuscle.
Dose limiting toxicity (DLT) and dose adjustments of
sunitinib
Adverse events occurring during intake of sunitinib until
4 weeks after completion of combined RT and sunitinib
were documented and classified according to common
toxicity criteria of adverse events (CTCAE 4.0) by weekly
study visits including clinical examination, interrogation
for adverse events, laboratory tests and ECG. DLTs were
defined as any toxicity that causes discontinuation of RT
for more than 6 days, toxicity classified grade 4 or 5 and
toxicity classified grade 3 with the exception of
hematologic toxicities, arterial hypertension if controlled
by adequate medication within 14 days and elevated
serum levels of liver and pancreas enzymes if not related
to clinical symptoms. Sunitinib was stopped and not
reintroduced in case of DLT. In case of grade 3
hematological toxicity sunitinib was reduced (37.5 mg to
25 mg to 12.5 mg daily) until recovery to grade 1 and
then reintroduced in the original dose. Furthermore the
protocol allowed a temporary dose reduction in case of
prolonged toxicity of any CTCAE grade on an individual
basis. All dose reductions were documented in detail.
Postoperative morbidity was assessed by a study visit be-
tween the 30th and 40th day after tumor resection and
also classified according to CTCAE 4.0.
Evaluation of treatment response
Imaging response was defined according to response
evaluation criteria in solid tumors (RECIST) by compar-
ing pre-treatment and preoperative magnetic resonance
imaging or computed tomography. Pathological response
was defined as the fraction of non-viable tumor tissue in
the resection specimen with cut-off points at fifty and
ninety per cent.
Results
Patients and tumor characteristics
A total of 10 patients were recruited. The cohort of dose
level 1 was extended from three to six patients as
planned in the study protocol since one of the first three
patients suffered dose limiting toxicity. Three patients
were treated at dose level 2 as planned in the study
protocol. One patient was recruited into the study but
actually did not meet all inclusion criteria after path-
ology review. Therefore this patient had to be excluded
from the analysis. The patient never started study treat-
ment and was treated by surgery alone. All following
analyses are based on the nine patients treated according
to the study protocol. Patient characteristics are depicted
in Table 1.
Toxicity of preoperative treatment
At dose level 1, 1/3 initially recruited patients developed
a DLT (grade 4 lymphopenia) but recovered completely
Table 1 Patient and tumor characteristics
Number of patients 9
Dose level 1 (25 mg sunitinib) 6
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after discontinuation of sunitinib. This patient had a
retroperitoneal dedifferentiated liposarcoma with a size
of 15 cm. The dose level 1 cohort was then expanded to
six patients. None of the following dose level 1 patients
developed DLT. At dose level 2, 0/3 patients developed
DLT.
The most frequent toxicity of any grade (8/9) and
most frequent grade 3 or 4 toxicity (5/9) was hemato-
toxicity. Hematotoxicity resolved in all patients before
surgery and no patient developed neutropenic fever.
Grade 3/4 hematotoxicity occurred at both dose levels
and in patients with tumors located in the retroperito-
neum as well as located in the extremities. No other
grade 3 toxicity occurred. Hematotoxicity was the most
frequent toxicity of any grade. Six out of nine patients
required dose adjustments due to toxicity. Five patients
had dose adjustments because of hematotoxicity and
one patient because of prolonged grade 2 mucositis.
Dose adjustments were necessary at both dose levels. In
5/6 patients with dose adjustments, dose reductions
were necessary after 4 or more weeks of treatment with
sunitinib. Radiation therapy was completed without tox-
icity related dose reductions or delays in all patients.
Toxicity within the radiation field did not exceed grade
2 in any patient. One patient had a break of radiation
therapy for one day due to gastrointestinal toxicity. All
other patients completed radiation therapy as planned.
Toxicity of combined treatment is summarized in
Table 2.
Surgery and postoperative morbidity
All patients underwent tumor resection within 4 to
10 (median 7) weeks after completion of preoperative
treatment. The four patients with extremity STS
underwent wide resection, one required reconstruc-
tion of the superficial femoral artery and one required
plastic reconstruction with a gastrocnemius flap.
Three out of four patients with retroperitoneal
sarcoma underwent multivisceral resection with colec-
tomy and nephrectomy, one patient with a retroperi-
toneal undifferentiated sarcoma was diagnosed with
several small size liver metastases at surgery and
underwent tumor resection with colectomy and with-
out nephrectomy. One patient had a chest wall sar-
coma and underwent tumor resection en bloc with
chest wall and upper lobe resection. Microscopic clear
margins for the primary tumor site were achieved in
7/9 patients and 2/9 patients had R1 (microscopically
incomplete) resections. Five out of nine patients de-
veloped postoperative complications and 2/9 patients
required re-interventions (Table 2). One patient with
extremity STS went back to theatre because of wound
dehiscence and one patient with a retroperitoneal sar-
coma had intraoperative bleeding, postoperative anas-
tomotic leakage and abscess formation. There was no
obvious difference in postoperative morbidity regard-
ing dose level (3/5 dose level 1 vs. 2/5 dose level 2,
p = 0.60) or sunitinib dose reductions (4/5 with dose
reduction, 1/5 without dose reduction, p = 0.40).
Table 2 Toxicity of study treatment and postoperative complications of the individual patients






1 1 Lower extremity neutropenia (3) thrombocytopenia (2) facial
edema (1) fatigue (1)
0 prolonged wound drainage (1)
1 2 Lower extremity - 0 wound dehiscence (3)
1 3 Retroperitoneal lymphopenia (4) neutropenia (3)
thrombocytopenia (3) gamma-glutamyl-
transferase elevation (2) arterial hypertension (2)
fatigue (1)
1 -
1 4 Retroperitoneal lymphopenia (3) neutropenia (2)
thrombocytopenia (1) genitourinary (2) diarrhea (2)
0 intraoperative bleeding (4) intraabd.
abscess (3) myocardial ischemia (3)
anastomotic leakage (3)
1 5 Retroperitoneal lymphopenia (3) neutropenia (2)
thrombocytopenia (1) arterial hypertension (2)
dry mouth (1) diarrhea (1)
1 -
1 6 Groin lymphocytopenia (3) neutropenia (1) diarrhea (2)
dysgeusia (1)
2 -
2 7 Retroperitoneal lymphopenia (2) neutropenia (2)
thrombocytopenia (1) nausea (2) dry mouth (2)
2 -
2 8 Lower extremity neutropenia (1) thrombocytopenia (1) vaginal
mucositis (2) hand foot syndrome (1) nausea (1)
oral mucositis (1) epistaxis (1)
2 prolonged wound drainage (2)
lymphedema (2)
2 9 Chest wall lymphopenia (3) neutropenia (1)
thrombocytopenia (1) oral mucositis (1) fatigue (1)
1 delayed wound healing (1)
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Treatment response and oncological outcome
Restaging before surgery showed partial response in one
patient, stable disease in seven patients, and progressive
disease in one patient (Table 3). The patient with pro-
gressive disease had a retroperitoneal undifferentiated
pleomorphic sarcoma with progression of the primary
tumor and two liver metastases at surgical exploration.
Pathological examination revealed ≥ 95 % non-viable tis-
sue in 3/9 resection specimens (Table 3). Histology of
these patients was dedifferentiated liposarcoma, synovial
sarcoma and undifferentiated pleomorphic sarcoma.
Median follow-up was 23 months (range 9–36 months,
Table 3). One patient developed a local recurrence of a
myxofibrosarcoma of the thigh within the radiation field
after 19 months. Three patients were diagnosed with
metastatic disease. One patient with metastatic disease
died during follow-up.
Discussion
The primary endpoint of this GISG phase I trial was to
determine the recommended dose of sunitinib given
concurrently with preoperative RT in locally advanced
soft tissue sarcoma patients. The most relevant toxicity
of combined RT and sunitinib was hematotoxicity. Eight
out of nine patients developed hematotoxicity, four out
of nine patients hematotoxicity grade 3 (CTCAE 4.0)
and one patient had a dose limiting grade 4 lymphope-
nia. According to the 3 + 3 design of the trial, the recom-
mended dose of sunitinib for further trials is 37.5 mg
given daily and continuously per os starting two weeks
prior to the first day and until the last day of RT.
Combined anti-angiogenic treatment was evaluated in
several other trials: Pazopanib, sorafenib, sunitinib and
bevacizumab were administered concurrently with RT to
determine toxicity of combined treatment as a primary
endpoint and to explore its efficacy (Table 4) [12–17].
All but one study demonstrated that the combination of
RT with anti-angiogenic drugs does not result in exces-
sive toxicity, does not interfere with a full dose adminis-
tration of RT and is not associated with higher than
expected postoperative morbidity. The toxicity profile of
combined treatment reflects the toxicity profile of the
administered anti-angiogenic drug(e.g. hepatotoxicity in
case of pazopanib or hematotoxicity in case of sunitinib)
meaning that the combination of the anti-angiogenic drug
with radiation therapy did not lead to unexpected adverse
events. It is remarkable though, that in the trials the pro-
portions of patients who suffered from grade 3 toxicities
were generally higher in the combination with RT com-
pared to anti-angiogenic monotherapy (e.g. hepatotoxicity
in case of pazopanib or hematotoxicity in case of suniti-
nib) [18, 19]. The increased grade of known and typical
toxicities may be attributed to the combination with RT.
It is well known that the RT dose administered to the
bone marrow has a relevant and overproportional influ-
ence on the occurrence and severity of hematotoxicity
when combined with chemotherapy as compared to RT
alone [20, 21]. The same appears to be true for concurrent
treatment with anti-angiogenic agents. Yet, there is no
obvious explanation for increased hepatotoxicity of com-
bined treatment compared to anti-angiogenic drug mono-
therapy since hepatotoxicity was also increased in patients
with extremity tumors with no radiation dose to the liver
[15]. Lewin et al. published the only trial that resulted in
unacceptable toxicity with severe hepatotoxicity and
hematotoxicity when RT was combined with sunitinib in
extremity STS [13]. Their results contradict our own
phase I trial and the results of Sunyach et al. who pre-
sented their data on combined RT and sunitinib in irre-
sectable extremity STS during the conference of the
connective tissue oncology society 2014 [16]. In principal,
the three trials used similar treatment regimens. Yet,
Table 3 Treatment response and oncological outcome






Follow-up status (and time),
events (months after ED)
1 lower extremity, myxofibrosarcoma,
11 cm
25 50.4 R0 stable disease 30 % NED (29mo), LR resected
(19 mo)
2 lower extremity, dediff. lipo, 8 cm 25 50.4 R0 stable disease 95 % AWD (36 mo), Soft tissue
mets (15 mo)
3 Retroperitoneal, dediff. lipo, 15 cm 25 50.4 R1 stable disease 75 % NED (28 mo)
4 Retroperitoneal, dediff. lipo, 12 cm 25 50.4 R1 stable disease 20 % NED (11 mo)
5 Retroperitoneal, undiff. pleomorphic
sarcoma, 14 cm




70 % DOD (9 mo), Liver mets at
surgery
6 Groin, Dediff. lipo, 20 cm 25 50.4 R0 stable disease 30 % NED (24 mo)
7 Retroperitoneal, myxoidlipo, 5 cm 37.5 50.4 R0 partial response 50 % NED (20 mo)
8 lower extremity, synovial sarcoma,
8 cm
37.5 50.4 R0 stabledisease 100 % AWD (23 mo), Lung mets
(15 mo)
9 chest wall, undiff. pleomorphic
sarcoma, 5 cm
37.5 50.4 R0 stabledisease 100 % NED (13 mo)
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Lewin et al. administered a higher starting dose (50 mg
for two weeks followed by 25 mg thereafter) which may
have resulted in higher toxicity.
The aim of combining anti-angiogenic drugs and RT is
to increase RT efficacy and to improve local tumor con-
trol. None of the above mentioned trials was designed as
a phase II or III trial. Nevertheless, most of the authors
presented data on pathological response as a surrogate
marker of treatment efficacy (Table 4). Although the
evaluation of pathologic response has not been standard-
ized until recently and the fraction of non-viable tumor
in the resection specimen depends on histological sub-
type, it may be used to estimate the efficacy of combined
modality treatment in general [22]. Noteworthy, more
than a third of the treated patients had tumors with less
than 10 % viable tumor cells in all five trials that re-
ported pathologic response (Table 4). This proportion
appears to be significantly higher than what would be
expected after preoperative RT alone [23]. This implies
that RT and anti-angiogenic drugs indeed have additive
effects. Serum biomarkers of angiogenesis and functional
imaging may be alternative surrogate markers for treat-
ment response. Yoon et al. and Lewin et al. performed
functional imaging studies after the run-in phase of
bevacizumab or sunitinib and after combined treatment,
respectively [13, 17]. Both groups applied different
imaging techniques (perfusion CT vs. PET-CT and func-
tional MRI) and found heterogeneous results after anti-
angiogenic monotherapy (no influence on median blood
flow vs. increased hypoxia, respectively) whereas com-
bined treatment led to decreased blood flow and tumor
hypoxia, respectively. Canter et al. evaluated the course
of the angiogenesis markers VEGF, EGF and PDGF
during neoadjuvant treatment [14]. Overall, there was no
significant difference in serum levels between treatment re-
sponders and non-responders. These results demonstrate
the difficulty to define reliable predictors of response to
combined RT and anti-angiogenic treatment. With PAZN-
TIS, a phase II/III trial has already been initiated by the
American Children’s Oncology Group that is sponsored by
the NCI. The trial will test preoperative RT vs. pazopanib/
RT vs. chemotherapy/RT vs. pazopanib/chemotherapy/RT
(ClinicalTrials.gov Identifier: NCT02180867). The PAZN-
TIS trial will use pathologic response with a cut off at 90 %,
serial PET-CT imaging and circulating DNA as surrogate
markers of response. Pediatric as well as adult patients may
be included with a number of restrictions in the eligibility
criteria for recruitment into the different treatment arms.
These restrictions and the fact that this is a four arm study
with pediatric and adult patients will render results difficult
to interpret. Yet, no other phase II/III study of combined
treatment has been initiated so far.
Conclusions
The combination of anti-angiogenic drugs and RT is
feasible and toxicity of combined treatment is tolerable.
Surgery appears to be safe after concurrent treatment
regimens. Further trials need to take into account histo-
logical subtypes. Surrogate markers of tumor response
are necessary to define the efficacy of neoadjuvant com-
bined RT and anti-angiogenic drug treatment in STS.
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Tumor site Patients with toxicity
(CTCAE)≥ grade 3
Type of toxicity (CTCAE)≥ grade 3 Path. response: ≥ 90 %
non-viable tissue
Haas 2015 11 Pazopanib/RT Extremity (n = 11) 3/11 Hepatotoxicity 4/10




Yoon 2011 20 Bevacizumab/RT Extremity (n = 13)
Retro (n = 6)
Trunk (n = 1)
4/20 Hepatotoxicity, hypertension 7/20




Jakob 2015 16 Sunitinib/RT Extremity (n = 5)
Retro (n = 10)
Trunk (n = 1)
8/16 Hematotoxicity, hand-foot-syndrome 5/16
Sunrase (this trial) 9 Sunitinib/RT Extremity (n = 3)
Retro (n = 4)
Trunk (n = 2)
5/9 Hematotoxicity 3/9
Sunyach 2014 10 Sunitinib/RT Extremity (n = 10) Only DLT reported Thrombopenia grade 4 (n = 1), no
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